ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use
Deepak L. Bhatt(Mount Sinai Hospital), Eamonn M.M. Quigley(Methodist Hospital), Kenneth W. Mahaffey(Cardiovascular Institute of the South), Neena S. Abraham(National Health Laboratory Service), Francis K.L. Chan(Chinese University of Hong Kong), David A. Johnson(University of Chicago), James M. Scheiman(University of Michigan), Curt D. Furberg(Wake Forest University), Elliott M. Antman(Brigham and Women's Hospital)
Cited by 845
Related Papers
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
|New England Journal of Medicine|2011|9.4k
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
|New England Journal of Medicine|2017|7.7k
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2009|7.1k
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation
|European Heart Journal|2012|6.8k
Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2007|6.7k